2021
Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung
Ramalingam S, Dinan M, Crawford J. Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. Clinical Lung Cancer 2021, 22: e646-e653. PMID: 33582071, DOI: 10.1016/j.cllc.2020.12.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMetastatic non-small cell lung cancerCommunity-based centersAcademic centersMetastatic non-small cell carcinomaNon-small cell carcinomaStudy periodPrimary end pointNational Cancer DatabaseCell lung cancerSquamous cell carcinomaCancer-related deathMost cancer-related deathsTreatment-related improvementOverall survivalSurvival gapSurvival disparitiesImproved survivalCell carcinomaLung cancerCancer DatabaseRetrospective analysisNew therapiesPatientsEnd point
2018
Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.
Wilson L, Greiner M, Altomare I, Rotter J, Dinan M. Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015. Journal Of Clinical Oncology 2018, 36: 23-23. DOI: 10.1200/jco.2018.36.30_suppl.23.Peer-Reviewed Original ResearchTargeted anti-cancer drugsCancer spendingCancer patientsD patientsBC patientsAnti-cancer drugsColorectal cancer populationPatients age 65Breast cancer patientsLung cancer patientsMedicare spendingElderly lungsElderly patientsPatient ageCC patientsLC patientsMedicare 5Colorectal cancerInvasive lungPatient populationCancer populationMedicare patientsNationwide utilizationRetrospective analysisMean cost
2017
Trends in hospital-physician integration in medical oncology.
Clough JD, Dinan MA, Schulman KA. Trends in hospital-physician integration in medical oncology. The American Journal Of Managed Care 2017, 23: 624-627. PMID: 29087634.Peer-Reviewed Original ResearchConceptsHospital outpatient departmentsMedical oncologyHigh-volume specialtiesOutpatient departmentMedical oncologistsMedical oncology practiceHospital-physician integrationProportion of physiciansGreater absolute changeManagement visitsThoracic surgeryOncology practiceRetrospective analysisOncologyAbsolute changeOncologistsMajority of evaluationsPhysiciansHigher proportionSpecialtiesDepartmentState-level variationYearsProportionSurgery
2015
Otolaryngology utilization of speech‐language pathology services for voice disorders
Cohen SM, Dinan MA, Kim J, Roy N. Otolaryngology utilization of speech‐language pathology services for voice disorders. The Laryngoscope 2015, 126: 906-912. PMID: 26308555, DOI: 10.1002/lary.25574.Peer-Reviewed Original ResearchConceptsLaryngeal/voice disordersSpeech-language pathology servicesSLP evaluationLaryngeal diagnosisDiagnosis changeSLP servicesVoice disordersMultivariable logistic regression analysisPathology servicesClinical Modification codesLogistic regression analysisVoice therapy sessionsPatient ageHealthcare utilizationInitial diagnosisPatient factorsNinth RevisionUnique patientsStudy criteriaVoice-disordered patientsRetrospective analysisStudy populationInternational ClassificationGreater oddsPatientsResource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer
Dinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, Reed SD. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: 28-37.e2. PMID: 26382223, PMCID: PMC4698191, DOI: 10.1016/j.clgc.2015.07.006.Peer-Reviewed Original ResearchConceptsEnd Results-Medicare dataEnd of lifeProstate cancerOutpatient settingOutpatient useRetrospective analysisMore hospicesLower mean inpatient costsSkilled nursing facility daysIntensive care unit daysIntensive care unit useJudicious careAndrogen deprivation therapyOverall health care costsUse of chemotherapyMean inpatient costsMultiple invasive proceduresHealth care costsSignificant financial burdenDeprivation therapyNoncancer causesICU useSingle strongest predictorUnit daysInpatient costs
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis
2013
Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study
Cohen SM, Dinan MA, Roy N, Kim J, Courey M. Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study. Otolaryngology 2013, 150: 95-102. PMID: 24264568, DOI: 10.1177/0194599813512982.Peer-Reviewed Original ResearchConceptsPrimary care physiciansOtolaryngology groupLaryngeal diagnosisInitial diagnosisClinical Modification codesHealth care utilizationVoice disordersLaryngeal cancer diagnosisNonspecific dysphoniaOutpatient visitsAcute laryngitisCare physiciansCare utilizationNinth RevisionPrimary careDifferential diagnosisRetrospective analysisAppropriate treatmentInclusion criteriaDiagnosis changeInternational ClassificationPatientsAccurate diagnosisLaryngeal disordersStudy designVariations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007. Radiology 2013, 267: 807-817. PMID: 23418003, DOI: 10.1148/radiol.12120174.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositron emission tomographyUse of PETMedicare beneficiariesCases of NSCLCPET useDiagnosis of NSCLCEnd Results-Medicare dataMultivariable logistic regression analysisDuke University Health SystemHalf of patientsCell lung cancerExamination 2 monthsMultivariable regression analysisUniversity Health SystemLogistic regression analysisDemographic subgroupsRegression analysisInstitutional review boardNonblack patientsPrimary outcomeFinal cohortSurveillance EpidemiologyLung cancerRetrospective analysis
2012
Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003. Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.Peer-Reviewed Original ResearchConceptsPositron emission tomographyOverall survivalStage migrationMedicare beneficiariesAdvanced diseasePET useEnd Results-Medicare dataEmission tomographyProportion of patientsStage IV diseaseCell lung cancerSelection biasUpstaging of diseaseGreater overall survivalStage-specific survivalStudy criteriaLung cancerSurvival AssociatedImproved outcomesRetrospective analysisStage distributionNSCLCPatientsDiseaseSurvival